SCHEMBL2406492

SCHEMBL2406492

C[C@@H](NS(=O)(=O)c1ccc(C(F)(F)F)cc1)c1cccc(C(=O)NO)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EEF2K O00418 2/20 0.49
HDAC8 Q9BY41 5/20 0.48
MMP7 P09237 2/20 0.47
MMP9 P14780 2/20 0.47
MMP13 P45452 2/20 0.47
MMP1 P03956 1/20 0.47
MMP2 P08253 1/20 0.47
MMP3 P08254 1/20 0.47
NPSR1 Q6W5P4 2/20 0.47
HDAC6 Q9UBN7 4/20 0.47
MMP10 P09238 1/20 0.46
KAT6A Q92794 2/20 0.46
ADAMTS4 O75173 1/20 0.46
GPR139 Q6DWJ6 1/20 0.45
POLB P06746 2/20 0.44
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
GAA P10253 1/20 0.44
CYP2D6 P10635 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2412670 0.87 MMP7 (0.52) EEF2KHDAC8MMP7MMP9MMP13
SCHEMBL2413093 0.87 MMP7 (0.52) EEF2KHDAC8MMP7MMP9MMP13
SCHEMBL2409579 0.82 NPSR1 (0.56) HDAC8NPSR1GPR139LMNACYP3A4
SCHEMBL2409492 0.82 NPSR1 (0.58) HDAC8MMP7MMP9MMP13MMP1
SCHEMBL2409731 0.81 HDAC8 (0.47) EEF2KHDAC8MMP7MMP9MMP13
SCHEMBL2409311 0.79 MMP7 (0.54) EEF2KHDAC8MMP7MMP9MMP13
SCHEMBL6919178 0.78 HDAC3 (0.52) EEF2KHDAC8MMP7MMP9MMP13
SCHEMBL12320083 0.78 MMP7 (0.48) EEF2KHDAC8MMP7MMP9MMP13
SCHEMBL2408091 0.76 HDAC8 (0.64) EEF2KHDAC8HDAC6POLBGAA
SCHEMBL6919174 0.75 ALKBH2 (0.49) EEF2KHDAC8MMP7MMP9MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US claimed
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US disclosed
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US disclosed
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed
WO-2011106632-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 WO disclosed
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC10, HDAC1 EEF2K 1208/4885HDAC8 15/4885MMP7 914/4885
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC10, HDAC1 EEF2K 1208/4885HDAC8 15/4885MMP7 914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.